BerGenBio, an emerging oncology biopharma, today announced the appointment of Heidi Pavliska to its Board of Directors. Pavliska was one of the original group of scientists in the start-up of Galapogos NV. She was instrumental in the development of their target discovery platform and was later responsible for its commercialization across Europe. More recently Mrs Pavliska was Director of Business Development with AMRI. Following a recent successful fundraising led by a syndicate of Norwegian investors, this appointment represents a further strengthening of the company as it gears up to commercialize its proprietary novel cancer targets through strategic alliances.
Richard Godfrey, BerGenBio’s CEO, welcomed Pavliska’s appointment: “Heidi brings to BerGenBio both a wealth of experience in the commercialization of technology platforms and development of first-in-class oncology therapeutic leads in collaborative commercial arrangements. We hope to utilize both her extensive network and industry experience as we widen access to the CellSellect technology platform and build risk-sharing development programs in the industry.
Mrs Pavliska added: “I am delighted to be joining BerGenBio at such an exciting time, havingI immediately recognised immense market potential of the CellSelect™ discovery platform.Coupled with the company’s strong scientific team and a refreshingly open minded approach to risk sharing commercial agreements, I look forward to supporting its business growth over the next few years.”
Notes to editors
BerGenBio AS is a biopharmaceutical company located in Bergen, Norway and founded on proprietary platform technology called CellSelect™. The CellSelect technology uses information from RNAi screening studies to identify novel drug targets involved in disease. BerGenBio has a deep understanding of Cancer biology and in particular the tumor micro-environment, EMT and mechanisms of drug resistance. Having generated significant fee for service revenues with CellSelect, BerGenBio AS is now transitioning to developing first in class oncology therapeutics through to phase II in partnership with industry leaders.
Richard Godfrey, CEO
Tel +47 917 86 304
Richard Hayhurst, Schwartz Communications
Tel +44 7950 878218